Marshall Wace
KROS icon

Marshall Wace’s Keros Therapeutics KROS Stock Holding History

Marshall Wace’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,500
Closed -$2.53M – 2805
2024
Q3 		$2.53M Buy
43,500
+21,123
+94% +$1.04M ﹤0.01% 1282
2024
Q2 		$1.02M Sell
22,377
-250,594
-92% -$13.5M ﹤0.01% 1679
2024
Q1 		$18.1M Buy
272,971
+223,499
+452% +$13.3M 0.03% 544
2023
Q4 		$1.97M Buy
+49,472
New +$1.55M ﹤0.01% 1229
2023
Q3 		– Sell
-62,650
Closed -$2.52M – 2465
2023
Q2 		$2.52M Sell
62,650
-53,870
-46% -$2.36M ﹤0.01% 1291
2023
Q1 		$4.98M Buy
116,520
+110,120
+1,721% +$5.56M 0.01% 1003
2022
Q4 		$307K Buy
+6,400
New +$299K ﹤0.01% 2560
2022
Q3 		– Sell
-52,934
Closed -$1.46M – 3582
2022
Q2 		$1.46M Buy
52,934
+45,466
+609% +$1.99M ﹤0.01% 2219
2022
Q1 		$406K Buy
7,468
+1,741
+30% +$89.4K ﹤0.01% 2863
2021
Q4 		$335K Sell
5,727
-43,909
-88% -$2.19M ﹤0.01% 2987
2021
Q3 		$1.96M Buy
49,636
+37,581
+312% +$1.34M 0.01% 1566
2021
Q2 		$512K Buy
12,055
+6,178
+105% +$335K ﹤0.01% 2113
2021
Q1 		$362K Sell
5,877
-11,615
-66% -$736K ﹤0.01% 2063
2020
Q4 		$1.23M Buy
+17,492
New +$1.1M 0.01% 1131

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Marshall Wace's KROS Position: Q4 2024 in Review

Marshall Wace sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 43,500 shares — an estimated $2.53M sold.

Marshall Wace first reported a position in KROS in Q4 2020 and held it in 14 quarters. The position peaked at $18.1M in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • Marshall Wace reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Marshall Wace sold 43,500 Keros Therapeutics shares in Q4 2024, an estimated $2.53M.
  • Marshall Wace first reported a position in Keros Therapeutics in Q4 2020 and held it in 14 quarters.
  • Marshall Wace's Keros Therapeutics position peaked at $18.1M in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.